Abstract
The systemic delivery of [E1(-)] adenoviral (Ad) vectors encoding a transgene results in efficient viral uptake and abundant transgene expression in the liver. However, [E1(-)]Ad vector persistence is transient due to cytotoxic T lymphocyte (CTL)-mediated loss of the Ad-infected cells. Our laboratory has previously demonstrated that additional modifications to the [E1(-)]Ad vector genome, by deletion of the Ad E2b genes, significantly decreased virus-genome-derived gene expression and simultaneously improved the long-term performance of the resultant [E1(-), E2b(-)]Ad vector. In this study, we confirmed that [E1(-), E2b(-)]Ad vector genomes could persist equally well in C57Bl/6 or Balb/c mouse hepatocytes. Despite vector genome persistence, we observed a strain-dependent variability in the duration of CMV enhancer/promoter-driven transgene expression in the liver. While Balb/c mice rapidly shut down [E1(-), E2b(-)]Ad-derived transgene expression, C57Bl/6 mice allowed for prolonged transgene expression. This occurred even when both strains were crossed into a severe combined immune-deficient background, demonstrating that host adaptive immune responses are not responsible for the phenomenon. Furthermore, differential methylation...Continue Reading
References
Jan 1, 1995·Annual Review of Immunology·S L Reiner, R M Locksley
Dec 1, 1994·Human Gene Therapy·H LochmüllerG Acsadi
Feb 16, 1996·Science·M L GülerK M Murphy
May 1, 1996·Nature Genetics·K F KozarskyJ M Wilson
Mar 1, 1996·Biological Chemistry Hoppe-Seyler·S PröschD H Krüger
Nov 1, 1996·Human Molecular Genetics·Y YangJ M Wilson
Jul 1, 1997·Human Gene Therapy·N MorralA Beaudet
May 1, 1997·Gene Therapy·A I MichouM Mehtali
Dec 31, 1997·Human Gene Therapy·L QinJ S Bromberg
Feb 27, 1999·Human Gene Therapy·H HuA Amalfitano
Apr 6, 1999·Journal of Neurovirology·P C CharlesC F Brosnan
Mar 1, 2000·Journal of Neuroimmunology·P C CharlesC F Brosnan
Aug 23, 2000·The Journal of Gene Medicine·B L HodgesA Amalfitano
May 18, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·R S SungJ S Bromberg
Jun 2, 2001·Human Gene Therapy·E Y DingA Amalfitano
Jun 23, 2001·Gene Therapy·A E LuebkeA Amalfitano
Nov 17, 2001·Journal of Virology·K R SpindlerA Kajon
Jan 5, 2002·Human Molecular Genetics·Julian D HarrisGeorge Dickson
Apr 12, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Enyu DingAndrea Amalfitano
Dec 13, 2003·Human Gene Therapy·R S EverettA Amalfitano
Citations
Nov 24, 2006·Journal of Virology·Zachary C HartmanAndrea Amalfitano
Jan 29, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sergey S SereginAndrea Amalfitano
Aug 13, 2013·Human Gene Therapy·Mei Hua GaoH Kirk Hammond
Sep 29, 2009·Expert Opinion on Biological Therapy·Sergey S Seregin, Andrea Amalfitano
Dec 25, 2012·Translational Research : the Journal of Laboratory and Clinical Medicine·Tong Tang, H Kirk Hammond
Jun 27, 2006·Journal of Cellular and Molecular Medicine·Rachel Aronoff, C C H Petersen
May 5, 2010·The Journal of Gene Medicine·Chia-Hui LoMi-Hua Tao
Sep 24, 2015·Human Gene Therapy Methods·Fabienne StollerJohannes Häberle
Jul 17, 2015·Gene Therapy·C ZhengI Alevizos
Mar 13, 2015·Human Gene Therapy Methods·Xiufang PanDongsheng Duan
Oct 10, 2006·Virology·Zachary C HartmanAndrea Amalfitano
Feb 19, 2008·Virology·Zachary C HartmanAndrea Amalfitano
Nov 9, 2016·Molecular Therapy. Nucleic Acids·Alastair G KerrRichard Wade-Martins
Apr 12, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Paula Y P LamKam M Hui
Jan 20, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alfred Y WangMark A Kay
Feb 3, 2006·Gene Therapy·C Le Bec, A M Douar
Aug 9, 2007·Physiological Genomics·Frank Park